Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Interest & Investment Income: 2023-2025

  • Tonix Pharmaceuticals Holding's Interest & Investment Income rose 6738.89% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 844.22%. This contributed to the annual value of $1.7 million for FY2023, which is 8.06% down from last year.
  • Tonix Pharmaceuticals Holding's Interest & Investment Income amounted to $1.2 million in Q3 2025, which was up 96.02% from $628,000 recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Interest & Investment Income registered a high of $1.2 million during Q3 2025, and its lowest value of $2,000 during Q2 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Interest & Investment Income value was $95,000 (recorded in 2023), while the average stood at $343,000.
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Interest & Investment Income slumped by 89.53% in 2024, and later surged by 31,300.00% in 2025.
  • Tonix Pharmaceuticals Holding's Interest & Investment Income (Quarterly) stood at $7,000 in 2023, then tumbled by 89.53% to $18,000 in 2024, then spiked by 6,738.89% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $628,000 for Q2 2025, and $18,000 during Q3 2024.